<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   The role of platelets in coronary heart disease
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       The role of platelets in coronary heart disease
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        The role of platelets in coronary heart disease
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jane E Freedman, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Freek Verheugt, MD, FACC, FESC
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Todd F Dardas, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 05, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Platelets play an important role in cardiovascular disease both in the pathogenesis of atherosclerosis and in the development of acute thrombotic events. Their importance in coronary disease and in acute coronary syndromes is indirectly confirmed by the benefit of antiplatelet agents (particularly
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         , and the glycoprotein IIb/IIIa inhibitors) in these disorders. (See
         <a class="medical medical_review" href="/z/d/html/95.html" rel="external">
          "Acute non-ST-elevation acute coronary syndromes: Early antiplatelet therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/94.html" rel="external">
          "Acute ST-elevation myocardial infarction: Antiplatelet therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16291.html" rel="external">
          "Aspirin in the primary prevention of cardiovascular disease and cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PLATELET ADHESION AND AGGREGATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both superficial and deep intimal injury disrupt the intact endothelium, which normally prevents the adherence of platelets by the production of the antiplatelet agents nitric oxide and prostacyclin. Disruption of the endothelium also exposes collagen. These factors lead to the adherence of platelets to the subendothelium, both directly and via von Willebrand factor, and, subsequently, to platelet activation  (
         <a class="graphic graphic_figure graphicRef63712" href="/z/d/graphic/63712.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         The following is a brief summary of platelet adhesion and aggregation. These processes are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6683.html" rel="external">
          "Platelet biology and mechanism of anti-platelet drugs"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Adhesion
         </span>
         <span class="headingEndMark">
          —
         </span>
         Platelet adhesion is mediated by the binding of platelet receptors to a number of arterial wall receptors, including subendothelial collagen (whose corresponding platelet receptor is glycoprotein [GP] Ia/IIa), von Willebrand factor (GP Ib/IX and GP IIb/III), and fibrinogen (GP IIb/IIIa).
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Activation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Binding of platelets to these structural proteins in concert with the action of soluble receptor-mediated stimulants, such as thrombin, adenosine diphosphate (ADP), and thromboxane A2 (TxA2), induces platelet activation. This process involves the mobilization of calcium from intracellular stores, the activation of several intracellular kinases, and the release of arachidonic acid from membrane phospholipids, resulting in the generation of TxA2  (
         <a class="graphic graphic_figure graphicRef70151" href="/z/d/graphic/70151.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid2">
          2
         </a>
         ]. Platelet activation produced in vivo is enhanced by circulating catecholamines [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Aggregation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Platelet aggregation results from conversion of the IIb/IIIa receptor to a form that can bind adhesive proteins, such as fibrinogen. This process is normally opposed by the secretion of nitric oxide and of prostacyclin (PGI2), another product of arachidonic acid metabolism, from the vascular endothelium.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Secretion
         </span>
         <span class="headingEndMark">
          —
         </span>
         During and after aggregation, platelets release many substances that can induce further platelet accumulation and activation, vasoconstriction, thrombosis, and mitogenesis, including adenosine diphosphate (ADP), serotonin, platelet-derived growth factor, fibroblast growth factor, platelet factor 4, and beta-thromboglobulin [
         <a href="#rid2">
          2,4
         </a>
         ]. Platelet-released serotonin normally causes vasodilation; however, it can induce vasoconstriction in the presence of damaged or abnormal (dysfunctional) endothelium [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         Activated platelets also release nitric oxide [
         <a href="#rid6">
          6,7
         </a>
         ]. This response may prevent an excessive response by inhibiting platelet recruitment to the growing thrombus [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          PATHOGENESIS OF THE ACUTE ISCHEMIC SYNDROME
         </span>
         <span class="headingEndMark">
          —
         </span>
         Angiographic severity of coronary stenosis does not adequately predict the location of subsequent coronary artery occlusion [
         <a href="#rid8">
          8
         </a>
         ]. Thus, rupture of atheromatous plaque and subsequent occlusive thrombus formation are believed to be responsible for most acute myocardial ischemic events, such as unstable angina and acute myocardial infarction [
         <a href="#rid9">
          9-12
         </a>
         ]. However, systemic effects, such as inflammation due to systemic disease or infection, are more widespread within the coronary circulation and lead to instability of multiple plaques. (See
         <a class="local">
          'Interaction of thrombosis, inflammation, and infection'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/115790.html" rel="external">
          "Mechanisms of acute coronary syndromes related to atherosclerosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Coronary thrombosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Coronary artery thrombosis is the final pathogenic mechanism of acute ischemic events, including myocardial infarction and sudden cardiac arrest. There are complex interactions among the atherosclerotic artery, endothelial injury and dysfunction, vasospasm, and platelet activation. Plaque rupture exposes thrombogenic subendothelial components, leading to platelet deposition and activation.
        </p>
        <p>
         The following observations are compatible with the importance of platelet thrombus formation in acute ischemic syndromes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thrombus formation within a coronary vessel is the acute precipitating event in most unstable ischemic coronary syndromes, as documented by angiographic and pathologic studies [
         <a href="#rid13">
          13,14
         </a>
         ]. Among patients with sudden death due to coronary thrombosis, the thrombi typically have a layered appearance indicative of episodic growth [
         <a href="#rid14">
          14
         </a>
         ]. Episodic growth may alternate with intermittent fragmentation of the thrombus, leading to distal embolization of both thrombus and platelet aggregates and microinfarction [
         <a href="#rid14">
          14,15
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/115790.html" rel="external">
          "Mechanisms of acute coronary syndromes related to atherosclerosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Aggregating platelets form the core of the growing thrombotic mass (white thrombus) at the disrupted plaque; the associated reduction in blood flow promotes upstream and/or downstream propagation of fibrin and red blood cell and leukocyte rich red thrombus [
         <a href="#rid16">
          16,17
         </a>
         ]. Both subendothelial tissue factor and activated platelets themselves serve as stimuli for thrombin generation [
         <a href="#rid18">
          18-20
         </a>
         ]. Platelets provide a membrane surface for the assembly of procoagulants, two of which (factors V and VIII) are released with activation. Persistent thrombotic occlusion of the coronary vessel leads to acute myocardial infarction.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased platelet-derived thromboxane A2 and other prothrombotic prostaglandin metabolites have been found in patients with acute myocardial infarction and unstable angina, providing biochemical support for platelet activation as the cause of these events [
         <a href="#rid14">
          14,21
         </a>
         ]. One prospective study, for example, found a phasic increase in the excretion of thromboxane A2 metabolites in 84 percent of episodes of unstable angina [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with unstable angina have elevated levels of P-selectin, an integral membrane protein involved in platelet adhesion, as well as adherence to immune cells [
         <a href="#rid22">
          22
         </a>
         ]. Pulsatile shear stress, as occurs in stenotic arteries, can cause platelet aggregation via an increased expression of P-selectin [
         <a href="#rid23">
          23
         </a>
         ]. Hydrodynamic shear stress, resulting from plaque rupture, can activate platelets and cause both platelet aggregation (via glycoprotein [GP] IIb/IIIa and von Willebrand factor) and platelet-mediated neutrophil aggregation via upregulation of P-selectin [
         <a href="#rid24">
          24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3983.html" rel="external">
          "Leukocyte-endothelial adhesion in the pathogenesis of inflammation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Although levels of P-selectin decrease during the first month after treatment, levels remain higher than normal even with therapy with GP IIb/IIIa inhibitors, suggesting continued platelet activation [
         <a href="#rid25">
          25
         </a>
         ]. This finding is consistent with serial angioscopic studies showing persistence of complex yellow plaque and thrombus after successful reperfusion at one month and later [
         <a href="#rid26">
          26
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/115790.html" rel="external">
          "Mechanisms of acute coronary syndromes related to atherosclerosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Aggregating platelets from patients with acute coronary syndromes produce less nitric oxide than those from patients with stable or no angina [
         <a href="#rid27">
          27
         </a>
         ]. Why this might occur is not known, but impaired nitric oxide production can enhance platelet aggregation and thrombus formation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Despite treatment with platelet inhibitors, patients with acute cardiovascular events have enhanced platelet reactivity even at baseline [
         <a href="#rid28">
          28
         </a>
         ]. However, no benefit for platelet function testing with corresponding medication adjustment was found in the setting of coronary disease when the testing was conducted before and soon after stenting [
         <a href="#rid29">
          29
         </a>
         ], and the use of widespread platelet function testing for medication guidance remains unclear.
        </p>
        <p>
        </p>
        <p>
         These findings are consistent with another platelet-related factor that has been associated with cardiovascular thrombosis, which is the presence of larger, more reactive platelets in patients with acute ischemic events [
         <a href="#rid30">
          30-32
         </a>
         ]. The increase in platelet size, which may be in compensation for a persistent decrease in platelet count, results from the ongoing consumption of platelets in unstable angina; this is not seen in acute myocardial infarction [
         <a href="#rid33">
          33
         </a>
         ]. In addition, platelets from patients with unstable angina, as determined by studying platelet aggregability ex vivo, are hyperaggregable [
         <a href="#rid34">
          34
         </a>
         ]. These effects promote thrombus growth, limitation of blood flow, and acute ischemia.
        </p>
        <p>
         Platelet reactivity is altered by a number of environmental factors, such as age, serum cholesterol, diabetes, catecholamine levels, cigarette smoking, obesity, and alcohol consumption. However, data from the Framingham Heart Study suggest that these factors play only a minor role, accounting for only 4 to 7 percent of variance; in contrast, estimates suggest that heritable factors play a major role, accounting for 20 to 30 percent of the overall variance in platelet aggregation [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Polymorphisms of platelet glycoprotein receptor genes
         </span>
         <span class="headingEndMark">
          —
         </span>
         The functions of the platelet GP receptors have been described above. It has been suggested that polymorphisms in these receptors are a risk factor for coronary artery thrombosis [
         <a href="#rid36">
          36
         </a>
         ], although data from Framingham suggest that these polymorphisms contribute minimally to platelet function [
         <a href="#rid35">
          35
         </a>
         ]. Associations have been described for GP IIIa polymorphisms [
         <a href="#rid37">
          37
         </a>
         ] and GP Ia/IIa polymorphisms [
         <a href="#rid38">
          38,39
         </a>
         ]. However, many of these findings have not been confirmed in larger studies [
         <a href="#rid35">
          35,40
         </a>
         ] or meta-analyses [
         <a href="#rid41">
          41,42
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Interaction of thrombosis, inflammation, and infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         The mechanism of action of most platelet inhibitors is inhibition of fibrinogen-dependent platelet-platelet association.
        </p>
        <p>
         Platelets are also involved in the inflammatory response and produce proinflammatory mediators such as platelet-derived growth factor, platelet factor 4, and transforming growth factor-beta, as well as CD40 ligand. Platelets possess many innate immune receptors that may be activated in the setting of infection. Patients with acute coronary syndromes have increased interactions between platelets (homotypic aggregates) and between platelets and leukocytes/neutrophils (heterotypic aggregates). These latter aggregates form when platelets are activated and adhere to circulating leukocytes or neutrophils.
        </p>
        <p>
         Accumulating information suggests that inflammation plays an important role during the thrombotic phase of acute coronary syndromes. Leukocytes and neutrophils bind to platelets via P-selectin and beta-2-integrin, a process that requires platelet production of platelet-activating factor [
         <a href="#rid43">
          43-46
         </a>
         ]. Leukocytes in turn may be able to enhance platelet aggregation [
         <a href="#rid47">
          47,48
         </a>
         ], and the relationship between platelet-dependent thrombosis and inflammation is also governed, in part, by the platelet-surface receptor CD40 and its binding of CD40 ligand. These interactions suggest a mechanism for the coupling of thrombosis and inflammation during cardiac ischemia and are consistent with the increase in unstable coronary syndromes seen post-infection that is widely thought to be platelet mediated [
         <a href="#rid49">
          49,50
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3983.html" rel="external">
          "Leukocyte-endothelial adhesion in the pathogenesis of inflammation"
         </a>
         .)
        </p>
        <p>
         Clinically, acute infections are associated with a transient increase in the risk of thrombotic vascular events, many due to platelet activation [
         <a href="#rid51">
          51
         </a>
         ]. In addition to thrombosis, platelets perform various immune functions during acute and chronic infections. For instance, patients with COVID-19 have been consistently noted to have enhanced clinical thrombosis presumed to be due to increased coagulation, enhanced platelet function inflammatory cytokines, endothelial damage, and activated immunity. Previous studies of patients with COVID-19 report hyperactive platelets with increased interleukin content [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H333167931">
         <span class="h1">
          THE EFFECT OF CARDIOVASCULAR RISK FACTORS ON PLATELET FUNCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Growing evidence suggests that enhanced platelet reactivity and thrombosis seen in acute coronary syndromes may be partially due to cardiovascular risk factors. Data have demonstrated that obese subjects may have hyper-reactive platelets or have a blunted response to platelet-inhibitory effect of
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         [
         <a href="#rid53">
          53
         </a>
         ] and the mechanism has been suggested to be leptin-dependent [
         <a href="#rid54">
          54
         </a>
         ]. Information on blood pressure is mixed, but it appears platelet reactivity is exaggerated in hypertensive patients in the setting of exercise [
         <a href="#rid55">
          55
         </a>
         ]. Lastly, diabetes has been associated with platelet hyperreactivity and the mechanism may be due to advanced glycation end products [
         <a href="#rid56">
          56
         </a>
         ]. Other evolving risk factors attributed to platelet-dependent arterial thrombosis include systemic lupus erythematosus and hormone replacement therapy [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          POSSIBLE ROLE OF PLATELETS IN ATHEROSCLEROSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         A role for platelets in the evolutionary phase of the atherosclerotic plaque is suggested by the following observations:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Platelets adhere to exposed subendothelium after endothelial injury and release vasoactive substances that induce smooth muscle cell migration and proliferation [
         <a href="#rid57">
          57,58
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Platelets may serve as a lipid source in the development of the fatty streak [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Platelets can promote foam cell formation even in the absence of hyperlipidemia [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         However, there is no direct clinical evidence that platelets contribute to coronary atherosclerosis [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Possible role in stable coronary disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Platelets may play a role in stable coronary artery disease. This hypothesis is supported by a study in which circulating degranulated or activated platelets, enhanced platelet reactivity, and an increase in circulating monocyte-platelet aggregates were demonstrated in such patients [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H101460356">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Platelet activation
         </strong>
         – Platelets are activated by sequential steps, including adhesion, platelet-platelet interaction, and recruitment, which leads to thrombus formation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Coronary artery thrombosis
         </strong>
         –
         <strong>
         </strong>
         This is the final pathogenic mechanism of acute ischemic events, including myocardial infarction and sudden cardiac arrest. There are complex interactions within the atherosclerotic artery, endothelial injury and dysfunction, vasospasm, and platelet activation. Plaque rupture exposes thrombogenic subendothelial components, leading to platelet deposition and activation. (See
         <a class="local">
          'Pathogenesis of the acute ischemic syndrome'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Platelet function
         </strong>
         – In the setting of arterial thrombosis, platelet function may be mediated by its interaction with immune cells and can be influenced by active infection.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Role in early atherosclerosis
         </strong>
         – Platelets may also have a role in the evolutionary phase of the atherosclerotic plaque. (See
         <a class="local">
          'Possible role of platelets in atherosclerosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1196897333">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff thank Dr. Joseph Loscalzo for his past contributions as an author to this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008; 359:938.
          </a>
         </li>
         <li class="breakAll">
          Ware, JA, Coller, BS. Platelet morphology, biochemistry and function. In: Williams' Hematology, Beutler, E, Lichtman, MA, Coller, BS, Kipps, TJ (Eds), McGraw Hill, New York 1994. p.1161.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lauri D, Cerletti C, de Gaetano G. Amplification of primary response of human platelets to platelet-activating factor: aspirin-sensitive and aspirin-insensitive pathways. J Lab Clin Med 1985; 105:653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stein B, Fuster V, Israel DH, et al. Platelet inhibitor agents in cardiovascular disease: an update. J Am Coll Cardiol 1989; 14:813.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McFadden EP, Clarke JG, Davies GJ, et al. Effect of intracoronary serotonin on coronary vessels in patients with stable angina and patients with variant angina. N Engl J Med 1991; 324:648.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen LY, Mehta JL. Further evidence of the presence of constitutive and inducible nitric oxide synthase isoforms in human platelets. J Cardiovasc Pharmacol 1996; 27:154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freedman JE, Loscalzo J, Barnard MR, et al. Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest 1997; 100:350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Little WC, Constantinescu M, Applegate RJ, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation 1988; 78:1157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davies MJ, Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med 1984; 310:1137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Falk E. Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis. Characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. Br Heart J 1983; 50:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92:657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacIsaac AI, Thomas JD, Topol EJ. Toward the quiescent coronary plaque. J Am Coll Cardiol 1993; 22:1228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303:897.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation 1985; 71:699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davies MJ, Thomas AC, Knapman PA, Hangartner JR. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. Circulation 1986; 73:418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ueda Y, Asakura M, Hirayama A, et al. Intracoronary morphology of culprit lesions after reperfusion in acute myocardial infarction: serial angioscopic observations. J Am Coll Cardiol 1996; 27:606.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sherman CT, Litvack F, Grundfest W, et al. Coronary angioscopy in patients with unstable angina pectoris. N Engl J Med 1986; 315:913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moreno PR, Bernardi VH, López-Cuéllar J, et al. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes. Circulation 1996; 94:3090.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ardissino D, Merlini PA, Ariëns R, et al. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet 1997; 349:769.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santos MT, Valles J, Marcus AJ, et al. Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. A new approach to platelet activation and recruitment. J Clin Invest 1991; 87:571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315:983.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ikeda H, Takajo Y, Ichiki K, et al. Increased soluble form of P-selectin in patients with unstable angina. Circulation 1995; 92:1693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merten M, Chow T, Hellums JD, Thiagarajan P. A new role for P-selectin in shear-induced platelet aggregation. Circulation 2000; 102:2045.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Konstantopoulos K, Neelamegham S, Burns AR, et al. Venous levels of shear support neutrophil-platelet adhesion and neutrophil aggregation in blood via P-selectin and beta2-integrin. Circulation 1998; 98:873.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ault KA, Cannon CP, Mitchell J, et al. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1999; 33:634.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ueda Y, Asakura M, Yamaguchi O, et al. The healing process of infarct-related plaques. Insights from 18 months of serial angioscopic follow-up. J Am Coll Cardiol 2001; 38:1916.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freedman JE, Ting B, Hankin B, et al. Impaired platelet production of nitric oxide predicts presence of acute coronary syndromes. Circulation 1998; 98:1481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frelinger AL 3rd, Furman MI, Linden MD, et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 2006; 113:2888.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montalescot G, Vicaut E, Collet JP. Bedside monitoring of antiplatelet therapy for coronary stenting. N Engl J Med 2013; 368:871.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erusalimsky JD, Martin JF. The regulation of megakaryocyte polyploidization and its implications for coronary artery occlusion. Eur J Clin Invest 1993; 23:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown AS, Hong Y, de Belder A, et al. Megakaryocyte ploidy and platelet changes in human diabetes and atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17:802.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Endler G, Klimesch A, Sunder-Plassmann H, et al. Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol 2002; 117:399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathur A, Robinson MS, Cotton J, et al. Platelet reactivity in acute coronary syndromes: evidence for differences in platelet behaviour between unstable angina and myocardial infarction. Thromb Haemost 2001; 85:989.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grande P, Grauholt AM, Madsen JK. Unstable angina pectoris. Platelet behavior and prognosis in progressive angina and intermediate coronary syndrome. Circulation 1990; 81:I16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Donnell CJ, Larson MG, Feng D, et al. Genetic and environmental contributions to platelet aggregation: the Framingham heart study. Circulation 2001; 103:3051.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simmonds RE, Hermida J, Rezende SM, Lane DA. Haemostatic genetic risk factors in arterial thrombosis. Thromb Haemost 2001; 86:374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carter AM, Ossei-Gerning N, Wilson IJ, Grant PJ. Association of the platelet Pl(A) polymorphism of glycoprotein IIb/IIIa and the fibrinogen Bbeta 448 polymorphism with myocardial infarction and extent of coronary artery disease. Circulation 1997; 96:1424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moshfegh K, Wuillemin WA, Redondo M, et al. Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of myocardial infarction: a case-control study. Lancet 1999; 353:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casorelli I, De Stefano V, Leone AM, et al. The C807T/G873A polymorphism in the platelet glycoprotein Ia gene and the risk of acute coronary syndrome in the Italian population. Br J Haematol 2001; 114:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marian AJ, Brugada R, Kleiman NS. Platelet glycoprotein IIIa PlA polymorphism and myocardial infarction. N Engl J Med 1996; 335:1071.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhu MM, Weedon J, Clark LT. Meta-analysis of the association of platelet glycoprotein IIIa PlA1/A2 polymorphism with myocardial infarction. Am J Cardiol 2000; 86:1000.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Castelnuovo A, de Gaetano G, Donati MB, Iacoviello L. Platelet glycoprotein receptor IIIa polymorphism PLA1/PLA2 and coronary risk: a meta-analysis. Thromb Haemost 2001; 85:626.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kirchhofer D, Riederer MA, Baumgartner HR. Specific accumulation of circulating monocytes and polymorphonuclear leukocytes on platelet thrombi in a vascular injury model. Blood 1997; 89:1270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ostrovsky L, King AJ, Bond S, et al. A juxtacrine mechanism for neutrophil adhesion on platelets involves platelet-activating factor and a selectin-dependent activation process. Blood 1998; 91:3028.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li N, Hu H, Lindqvist M, et al. Platelet-leukocyte cross talk in whole blood. Arterioscler Thromb Vasc Biol 2000; 20:2702.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hu H, Varon D, Hjemdahl P, et al. Platelet-leukocyte aggregation under shear stress: differential involvement of selectins and integrins. Thromb Haemost 2003; 90:679.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faraday N, Scharpf RB, Dodd-o JM, et al. Leukocytes can enhance platelet-mediated aggregation and thromboxane release via interaction of P-selectin glycoprotein ligand 1 with P-selectin. Anesthesiology 2001; 94:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Del Maschio A, Evangelista V, Rajtar G, et al. Platelet activation by polymorphonuclear leukocytes exposed to chemotactic agents. Am J Physiol 1990; 258:H870.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koupenova M, Kehrel BE, Corkrey HA, Freedman JE. Thrombosis and platelets: an update. Eur Heart J 2017; 38:785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwong JC, Schwartz KL, Campitelli MA, et al. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. N Engl J Med 2018; 378:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smeeth L, Thomas SL, Hall AJ, et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004; 351:2611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manne BK, Denorme F, Middleton EA, et al. Platelet gene expression and function in patients with COVID-19. Blood 2020; 136:1317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tamminen M, Lassila R, Westerbacka J, et al. Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects. Int J Obes Relat Metab Disord 2003; 27:907.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Konstantinides S, Schäfer K, Koschnick S, Loskutoff DJ. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest 2001; 108:1533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gkaliagkousi E, Gavriilaki E, Yiannaki E, et al. Platelet activation in essential hypertension during exercise: pre- and post-treatment changes with an angiotensin II receptor blocker. Am J Hypertens 2014; 27:571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhu W, Li W, Silverstein RL. Advanced glycation end products induce a prothrombotic phenotype in mice via interaction with platelet CD36. Blood 2012; 119:6136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoak JC. Platelets and atherosclerosis. Semin Thromb Hemost 1988; 14:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357:2482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           CHANDLER AB, HAND RA. Phagocytized platelets: a source of lipids in human thrombi and atherosclerotic plaques. Science 1961; 134:946.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mendelsohn ME, Loscalzo J. Role of platelets in cholesteryl ester formation by U-937 cells. J Clin Invest 1988; 81:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elwood PC, Renaud S, Beswick AD, et al. Platelet aggregation and incident ischaemic heart disease in the Caerphilly cohort. Heart 1998; 80:578.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furman MI, Benoit SE, Barnard MR, et al. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol 1998; 31:352.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1498 Version 22.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18753650" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Mechanisms of thrombus formation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18753650" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Mechanisms of thrombus formation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3923145" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Amplification of primary response of human platelets to platelet-activating factor: aspirin-sensitive and aspirin-insensitive pathways.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2677086" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Platelet inhibitor agents in cardiovascular disease: an update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1994247" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Effect of intracoronary serotonin on coronary vessels in patients with stable angina and patients with variant angina.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8656650" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Further evidence of the presence of constitutive and inducible nitric oxide synthase isoforms in human platelets.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9218511" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Nitric oxide released from activated platelets inhibits platelet recruitment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3180375" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6709008" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6882602" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis. Characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7634481" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Coronary plaque disruption.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8104965" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Toward the quiescent coronary plaque.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7412821" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3971539" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3948352" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8606271" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Intracoronary morphology of culprit lesions after reperfusion in acute myocardial infarction: serial angioscopic observations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3489893" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Coronary angioscopy in patients with unstable angina pectoris.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8989114" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9074577" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Tissue-factor antigen and activity in human coronary atherosclerotic plaques.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1991840" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. A new approach to platelet activation and recruitment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3531859" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Platelet activation in unstable coronary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7545552" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Increased soluble form of P-selectin in patients with unstable angina.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11044418" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : A new role for P-selectin in shear-induced platelet aggregation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9738642" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Venous levels of shear support neutrophil-platelet adhesion and neutrophil aggregation in blood via P-selectin and beta2-integrin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10080462" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11738294" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : The healing process of infarct-related plaques. Insights from 18 months of serial angioscopic follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9769300" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Impaired platelet production of nitric oxide predicts presence of acute coronary syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16785341" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23445100" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Bedside monitoring of antiplatelet therapy for coronary stenting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8444270" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : The regulation of megakaryocyte polyploidization and its implications for coronary artery occlusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9108797" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Megakaryocyte ploidy and platelet changes in human diabetes and atherosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11972524" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11434707" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Platelet reactivity in acute coronary syndromes: evidence for differences in platelet behaviour between unstable angina and myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2136815" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Unstable angina pectoris. Platelet behavior and prognosis in progressive angina and intermediate coronary syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11425767" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Genetic and environmental contributions to platelet aggregation: the Framingham heart study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11487027" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Haemostatic genetic risk factors in arterial thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9315527" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Association of the platelet Pl(A) polymorphism of glycoprotein IIb/IIIa and the fibrinogen Bbeta 448 polymorphism with myocardial infarction and extent of coronary artery disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9950439" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of myocardial infarction: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11472360" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : The C807T/G873A polymorphism in the platelet glycoprotein Ia gene and the risk of acute coronary syndrome in the Italian population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8801456" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Platelet glycoprotein IIIa PlA polymorphism and myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11053714" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Meta-analysis of the association of platelet glycoprotein IIIa PlA1/A2 polymorphism with myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11341496" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Platelet glycoprotein receptor IIIa polymorphism PLA1/PLA2 and coronary risk: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9028950" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Specific accumulation of circulating monocytes and polymorphonuclear leukocytes on platelet thrombi in a vascular injury model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9531616" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : A juxtacrine mechanism for neutrophil adhesion on platelets involves platelet-activating factor and a selectin-dependent activation process.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11116075" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Platelet-leukocyte cross talk in whole blood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14515189" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Platelet-leukocyte aggregation under shear stress: differential involvement of selectins and integrins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11135734" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Leukocytes can enhance platelet-mediated aggregation and thromboxane release via interaction of P-selectin glycoprotein ligand 1 with P-selectin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2156456" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Platelet activation by polymorphonuclear leukocytes exposed to chemotactic agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28039338" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Thrombosis and platelets: an update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29365305" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15602021" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Risk of myocardial infarction and stroke after acute infection or vaccination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32573711" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Platelet gene expression and function in patients with COVID-19.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12861231" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11714745" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23975222" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Platelet activation in essential hypertension during exercise: pre- and post-treatment changes with an angiotensin II receptor blocker.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22431576" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Advanced glycation end products induce a prothrombotic phenotype in mice via interaction with platelet CD36.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3061006" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Platelets and atherosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18077812" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Platelet activation and atherothrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13692295" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Phagocytized platelets: a source of lipids in human thrombi and atherosclerotic plaques.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3335643" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Role of platelets in cholesteryl ester formation by U-937 cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10065026" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Platelet aggregation and incident ischaemic heart disease in the Caerphilly cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9462579" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
